- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Siemens to feature IT quality measures
Siemens to feature IT quality measuresWood heads image analysis firm
Siemens to feature IT quality measures
Siemens will demonstrate on Oct. 4 how its Soarian Quality Measures product saves time and improves accuracy associated with chart abstraction, as well as prepares users for Medicare’s upcoming plans to increase the number of core quality measures. The presentation will be part of an educational breakout session at the American Health Information Management Association Convention and Exhibit in Grapevine, TX. The company will also feature Soarian Quality Measures in its booth among other information technology tools that offer plan-of-care functionality, enterprise document management, and state-of-the-art data mining and reporting.
Wood heads image analysis firm
Susan A. Wood, Ph.D., is the new president and CEO of VIDA Diagnostics, a developer of quantitative imaging software used in clinical research to analyze pulmonary diseases, including asthma and lung cancer, and chronic obstructive pulmonary disease. Wood succeeds John Garber, who helped build VIDA from an academic concept. Wood will focus on the continued development and commercialization of the company's FDA-cleared pulmonary applications, while transitioning quantitative pulmonary imaging into routine clinical practice. Wood joined VIDA's board last year. Previously she served as executive vice president of marketing and technology at Vital Images and led marketing and new product development at R2 Technology, now part of Hologic.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
